Patents Assigned to Beth Israel Deaconess Medical Center, Inc.
-
Publication number: 20240092935Abstract: The present disclosure provides anti-Tn antibodies (e.g., BaGs6 and/or Remab6) having superior specificity for Tn antigen on cancer cells. Also provided herein, are nucleic acids, vectors, or vector sets that encode the anti-Tn antibody.Type: ApplicationFiled: October 9, 2020Publication date: March 21, 2024Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: Richard D. Cummings, Elliot Chaikof, Yasuyuki Matsumoto, Matthew R. Kudelka
-
Patent number: 11931163Abstract: Described herein are embodiments of an approach to diagnosing pancreatic cystic lesions using light scattering spectroscopy. In some embodiments, the approach includes an apparatus including a spatial gating probe to isolate light reflected by the epithelial tissue of the internal cyst surface using spatial gating. In some further embodiments, the apparatus includes a scanning fiber probe that is capable of rotational and linear motion in order to scan the entire internal surface of the cyst. Use of such an approach may be advantageous to improve the accuracy of diagnosing pancreatic cystic lesions as cancerous, precancerous, or benign.Type: GrantFiled: February 23, 2018Date of Patent: March 19, 2024Assignee: Beth Israel Deaconess Medical Center, Inc.Inventor: Lev T. Perelman
-
Patent number: 11926824Abstract: Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.Type: GrantFiled: March 23, 2020Date of Patent: March 12, 2024Assignees: Board of Regents, The University of Texas System, Beth Israel Deaconess Medical Center, Inc.Inventors: Raghu Kalluri, Sónia Melo
-
Patent number: 11872241Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.Type: GrantFiled: November 26, 2019Date of Patent: January 16, 2024Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.Inventors: Jeffrey I. Zwicker, Bruce Furie, Jack Davis Stopa, Robert Flaumenhaft
-
Publication number: 20240009420Abstract: The present disclosure generally relates, in certain embodiments, to light-based treatments. In some case, a subject having or at risk for a condition such as insomnia can be treated, e.g., with light, such as green light. Other conditions include sleep disorders such as sleep apnea and other indications. In some cases, the light that is administered to the subject may be green light, or the light may have a characteristic wavelength only in a wavelength range between 510 nm and 550 nm with a bandwidth no larger than 20 nm full-width-half-maximum. Other embodiments described herein are generally directed to systems for treating such conditions, kits for treating such conditions, or the like.Type: ApplicationFiled: November 12, 2021Publication date: January 11, 2024Applicants: Haven Technologies Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Rami Burstein, Mark Severs, Jeff Sheely, Ajay Shashidar Kori
-
Publication number: 20230408376Abstract: Provided herein are systems for determining a stretch condition of a tissue and assessing the stiffness of the tissue. Also provided herein are methods for using the systems for measuring stiffness of a tissue, assessing the effect of an agent on a tissue, and identifying subjects having a disease or disorder associated with increased or decreased stiffness of a tissue.Type: ApplicationFiled: June 16, 2023Publication date: December 21, 2023Applicants: Trustees of Boston University, Beth Israel Deaconess Medical Center, Inc.Inventors: Bela Suki, Jae Hun Kim, Joseph Hall, Ramaswamy Krishnan, Niccole Schaible
-
Patent number: 11845788Abstract: Featured are PGT121 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating subjects infected with HIV and/or blocking HIV infections in subjects at risk of HIV transmission using the PGT121 variant antibodies or fragments thereof.Type: GrantFiled: May 22, 2019Date of Patent: December 19, 2023Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Dan H. Barouch, Bruce A. Kerwin, Randal R. Ketchem, Alison J. Gillespie, Christine C. Siska, Rutilio H. Clark, Julee A. Floyd, Jeremy M. Shaver, Richard S. Rogers
-
Patent number: 11834508Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.Type: GrantFiled: March 16, 2021Date of Patent: December 5, 2023Assignees: Novartis AG, Beth Israel Deaconess Medical Center, Inc.Inventors: Anthony Rosenzweig, Jason D. Roh, David J. Glass
-
Publication number: 20230382980Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: August 17, 2022Publication date: November 30, 2023Applicants: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20230364243Abstract: PROTACs (PROteolysis TArgeting Chimeras) are an emerging class of promising therapeutic modalities that degrade intracellular protein targets by hijacking the cellular ubiquitin-proteasome system. However, potential toxicity of PROTACs in normal cells due to off-tissue on-target degradation effect limits their clinical applications. Precise control of PROTAC's on-target degradation activity in a tissue selective manner could minimize potential toxicity/side-effects. To this end, we developed a cancer cell selective delivery strategy for PROTACs by conjugating a folate group to ubqiquitin recruitment moiety to achieve targeted degradation of proteins of interest (POIs) in cancer cells versus normal cells. We show that our folate-PROTACs, including BRD PROTAC (Folate-ARV-771), MEK PROTAC (Folate-MS432) and ALK PROTAC (Folate-MS99, Folate-S2-MS4048) are capable of degrading BRDs, MEKs and ALK, respectively, in a folate receptor-dependent manner.Type: ApplicationFiled: July 31, 2023Publication date: November 16, 2023Applicants: Beth Israel Deaconess Medical Center, Inc., Icahn School of Medicine at Mount SinaiInventors: Wenyi WEI, Jian JIN, Husnu Ümit KANISKAN, He CHEN, Jing LIU
-
Publication number: 20230346286Abstract: Described herein are embodiments of methods and apparatus for diagnosing neuromuscular diseases using an impedance-EMG needle, and for generating electrical impedance images using an impedance needle. Some embodiments provide an apparatus including an impedance-EMG needle, including both EMG electrodes and impedance electrodes, to measure both active and passive electrical properties of muscle. Other embodiments provide an apparatus including an impedance needle, including a plurality of impedance electrodes to measure impedance in tissue surrounding the impedance needle to generate an electrical impedance image. Use of such methods and apparatus may be advantageous in improving the accuracy of assessing and diagnosing neuromuscular disease.Type: ApplicationFiled: June 15, 2023Publication date: November 2, 2023Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: Benjamin Sanchez, Seward B. Rutkove, Hyeuknam Kwon
-
Patent number: 11802872Abstract: The invention provides a method for preparing an expanded renal (kidney) tissue sample suitable for microscopic analysis. Expanding the kidney sample can be achieved by binding, e.g., anchoring, key biomolecules to a polymer network and swelling, or expanding, the polymer network, thereby moving the biomolecules apart as further described herein. As the biomolecules are anchored to the polymer network, isotropic expansion of the polymer network retains the spatial orientation of the biomolecules resulting in an expanded, or enlarged, kidney sample.Type: GrantFiled: August 15, 2019Date of Patent: October 31, 2023Assignees: Massachusetts Institute of Technology, Beth Israel Deaconess Medical Center, Inc.Inventors: Edward Stuart Boyden, Andrew Hanno Beck, Yongxin Zhao, Octavian Bucur
-
Patent number: 11795213Abstract: The invention features the treatment of gastrointestinal disorders associated with an innate immune response triggered by alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM 16, CMb, CMX1/CMX3, CMX2, and/or alpha amylase inhibitor 0.53 (0.53). To this end, the invention features pharmaceutical compositions including neutralizing antibodies to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53, food products containing reduced levels of CM3, 0.19, CM1, CM2, CMa, CMd, CM1 6, CMb, CMX1/CMX3, CMX2, and/or 0.53 protein, the use of oral TLR4 inhibitors to block the effect of said alpha-amylase inhibitors, assays for identifying CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 content in food products, and assays for diagnosing subjects with a disorder related to CM3, 0.19, CM1, CM2, CMa, CMd, CM 16, CMb, CMX1/CMX3, CMX2, and/or 0.53 triggered innate immune responses.Type: GrantFiled: August 1, 2017Date of Patent: October 24, 2023Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Detlef Schuppan, Yvonne Junker, Towia Aron Libermann, Simon T. Dillon
-
Patent number: 11773142Abstract: Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).Type: GrantFiled: December 11, 2018Date of Patent: October 3, 2023Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Dan H. Barouch, Peter Abbink, Mark Justin Iampietro, Menzo J. E. Havenga
-
Patent number: 11774444Abstract: Methods and apparatus for detecting cell-bound and soluble antigens in a biological sample are described. The method comprises forming complexes of at least one antibody-coated bead and at least one antigen in a solution, placing the solution in a magnetic field such that the formed complexes levitate in the solution at a particular height, and determining at least one characteristic of the antigen in the complexes based, at least in part, on an image of the complexes showing the magnetic levitation height.Type: GrantFiled: November 10, 2017Date of Patent: October 3, 2023Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Ionita C. Ghiran, Nathan Shapiro, Anish V. Sharda, Edward J. Felton
-
Publication number: 20230278986Abstract: Provided are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, isotopically labeled derivatives, polymorphs, and prodrugs thereof, wherein X1—X4, RX, RC, RB, n, and Ring A are as defined herein. The compounds may be aryl hydrocarbon receptor agonists or partial aryl hydrocarbon receptor agonists. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and methods of using such compounds for treating diseases and conditions related to the activity of an aryl hydrocarbon receptor, such as, for example, inflammatory diseases, autoimmune diseases, metabolic disorders, and proliferative diseases.Type: ApplicationFiled: March 9, 2023Publication date: September 7, 2023Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: Elliot Chaikof, Lijun Sun
-
Patent number: 11737797Abstract: The apparatus, systems and methods disclosed herein generally relate to the surgical repair or alteration of bone. More particularly, certain of the disclosed apparatus, systems and methods of the present disclosure relate to the use of a directionally-reinforced composite material to emulate anisotropic structural characteristics of an original anatomic trabecular structure. The directionally-reinforced composite material may generally include a scaffold set in a composite matrix, wherein the scaffold determines the anisotropic structural characteristics of the materials. In some of the embodiments, a scaffold may include at least a first plurality of struts which are generally aligned in a first direction and a second plurality of struts aligned in a second direction.Type: GrantFiled: April 24, 2019Date of Patent: August 29, 2023Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Edward K. Rodriguez, Ara Nazarian
-
Patent number: 11730410Abstract: Described herein are embodiments of methods and apparatus for diagnosing neuromuscular diseases using an impedance-EMG needle, and for generating electrical impedance images using an impedance needle. Some embodiments provide an apparatus including an impedance-EMG needle, including both EMG electrodes and impedance electrodes, to measure both active and passive electrical properties of muscle. Other embodiments provide an apparatus including an impedance needle, including a plurality of impedance electrodes to measure impedance in tissue surrounding the impedance needle to generate an electrical impedance image. Use of such methods and apparatus may be advantageous in improving the accuracy of assessing and diagnosing neuromuscular disease.Type: GrantFiled: May 16, 2018Date of Patent: August 22, 2023Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Benjamin Sanchez, Seward B. Rutkove, Hyeuknam Kwon
-
Patent number: 11723957Abstract: The present invention provides methods for treating a stiffened joint in a subject that comprise administering relaxin, e.g., a PEGylated relaxin-2, to the subject. The relaxin may be administered intra-articularly as a sustained release formulation. The present invention also provides sustained release formulations in the form of a hydrogel for administering polypeptides that are covalently attached to a polymer, e.g., PEG.Type: GrantFiled: October 9, 2017Date of Patent: August 15, 2023Assignees: Beth Israel Deaconess Medical Center, Inc., Trustees of Boston UniversityInventors: Ara Nazarian, Edward Rodriguez, Mark Grinstaff
-
Patent number: 11718664Abstract: The present invention relates to methods for selecting a headache patient responsive to treatment with an anti-CGRP antibody and to methods for reducing headache frequency in the selected patient comprising administering an anti-CGRP antibody.Type: GrantFiled: August 18, 2020Date of Patent: August 8, 2023Assignee: Beth Israel Deaconess Medical Center, Inc.Inventor: Rami Burstein